LY3154885 / Eli Lilly - LARVOL DELTA

Synthesis and Preclinical Characterization of LY3154885, a Human Dopamine D1 Receptor Positive Allosteric Modulator with an Improved Nonclinical Drug-Drug Interaction Risk Profile. (PubMed, J Med Chem) - "Results from recently completed clinical studies suggest the dopamine D1 receptor positive allosteric modulator (PAM) mevidalen (1) could offer unique value for lewy body dementia (LBD) patients. While attempts to introduce additional metabolic pathways mediated by other CYP isoforms failed to provide molecules with an acceptable profile, we discovered that the relative contribution of CYP-mediated oxidation and UGT-mediated conjugation could be tuned to reduce the CYP3A4-mediated victim DDI risk. We have identified LY3154885 (5), a D1 PAM that possesses similar in vitro and in vivo pharmacologic properties as 1, but is metabolized mainly by UGT, predicting it could potentially offer lower victim DDI risk in clinic."

Journal • Preclinical • Alzheimer's Disease • CNS Disorders • Dementia • Lewy Body Disease

A Study of LY3154885 in Healthy Participants (clinicaltrials.gov) - P1; N=36; Terminated; Sponsor: Eli Lilly and Company; N=102 ➔ 36; Trial completion date: Jan 2021 ➔ Feb 2020; Suspended ➔ Terminated; Trial primary completion date: Jan 2021 ➔ Feb 2020; HUAA study is terminated early due to a business decision.

Clinical • Enrollment change • Trial completion date • Trial primary completion date • Trial termination

A Study of LY3154885 in Healthy Participants (clinicaltrials.gov) - P1; N=102; Suspended; Sponsor: Eli Lilly and Company; Trial completion date: Oct 2020 ➔ Jan 2021; Recruiting ➔ Suspended; Trial primary completion date: Oct 2020 ➔ Jan 2021

Clinical • Trial completion date • Trial primary completion date • Trial suspension

A Study of LY3154885 in Healthy Participants (clinicaltrials.gov) - P1; N=102; Recruiting; Sponsor: Eli Lilly and Company; Trial completion date: Apr 2020 ➔ Nov 2020; Trial primary completion date: Apr 2020 ➔ Nov 2020

Clinical • Trial completion date • Trial primary completion date

A Study of LY3154885 in Healthy Participants (clinicaltrials.gov) - P1; N=102; Recruiting; Sponsor: Eli Lilly and Company; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open